TORONTO, April 27 /CNW/ - Transition Therapeutics Inc. ("Transition")
(TSX: TTH), announced today that they have received clearance from the
Therapeutic Products Directorate of Health Canada to initiate a Phase I
clinical trial for lead Alzheimer's product, AZD-103. The AZD-103 compound is
a promising disease-modifying therapeutic candidate for the treatment of
Alzheimer's disease. This unique class of therapeutics provides significant
advantages over the current products on the market which only treat disease
symptoms.
